How to transfer my Mounjaro prescription to Florida

If you’re considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’ve probably wondered: Can I actually get these prescribed through telehealth? The short answer is yes—in most cases, you can legally obtain these medications via online consultation without ever stepping into a doctor’s office.

But as with many aspects of healthcare, the details matter. State regulations, provider qualifications, and clinical requirements vary significantly across the U.S. This comprehensive guide breaks down everything you need to know about accessing weight loss medications through telehealth in 2025, including state-specific rules, what to expect during your virtual visit, and how to ensure you’re working with a legitimate provider.

Understanding Federal Telehealth Rules for Weight Loss Medications

Let’s start with the good news: GLP-1 medications like Wegovy, Ozempic, and Mounjaro are not controlled substances under federal law. This is a crucial distinction that makes telehealth prescribing much simpler.

The Ryan Haight Act—a federal law that requires an in-person examination before prescribing controlled substances via telemedicine—does not apply to these medications. This means there’s no federal barrier preventing a licensed healthcare provider from prescribing semaglutide or tirzepatide after a virtual consultation.

What Changed During COVID-19?

The pandemic accelerated telehealth adoption across all areas of healthcare. While the Drug Enforcement Administration (DEA) implemented temporary flexibilities for controlled substances during the public health emergency, these changes primarily affected medications like Adderall, opioids, and anxiety medications—not GLP-1 drugs for weight loss.

As of December 2025, the DEA has extended these telehealth flexibilities for controlled substances through December 31, 2025, with additional extensions expected. However, this doesn’t impact GLP-1 prescribing, which has remained consistently accessible via telehealth throughout the pandemic and beyond.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Variations: Where the Rules Really Matter

While federal law is permissive, individual states have their own requirements for telehealth prescribing. Some states have embraced virtual weight management care with minimal restrictions, while others maintain stricter standards that may require an initial in-person visit or specific follow-up protocols.

States with No In-Person Requirement

Several states allow healthcare providers to prescribe GLP-1 medications entirely through telehealth:

• California: Full telehealth prescribing is permitted with no mandatory in-person visits. The state’s progressive telehealth laws, combined with independent nurse practitioner practice authority, make California one of the most accessible states for online weight loss treatment.

• Connecticut: Providers can prescribe via telehealth but must include behavioral counseling and a diet/exercise plan as part of obesity treatment. This holistic approach ensures patients receive comprehensive care, not just medication.

• Illinois: No special restrictions on telehealth weight loss prescribing beyond standard medical practice. Electronic prescribing is mandatory for all medications.

• New York: Telehealth exams are considered equivalent to in-person visits for establishing a patient-provider relationship. Nurse practitioners can practice independently after gaining 3,600 hours of experience.

• Pennsylvania: No in-person mandate for GLP-1 prescriptions. The state’s 2020 telehealth law has made virtual care a permanent option.

• Washington: As a pioneering telehealth state, Washington fully permits online prescribing with no in-person requirements. The state also has strong patient privacy protections under the My Health My Data Act.

States Requiring an Initial In-Person Visit

A handful of states mandate that patients undergo an initial physical examination before receiving GLP-1 prescriptions:

• Arkansas: One of the most restrictive states for telemedicine, Arkansas requires an initial in-person exam to establish the doctor-patient relationship. However, proposals to ease these restrictions were under review in late 2025.

• Delaware: Patients must complete an initial in-person evaluation before transitioning to telehealth follow-ups.

• Georgia: State policy requires an in-person exam prior to prescribing weight loss medications via telehealth. However, Georgia recently expanded nurse practitioner prescribing authority for Schedule II medications (though GLP-1s aren’t controlled substances).

• Mississippi: An initial in-person evaluation for weight management therapy is required by state law. Legislative efforts to grant nurse practitioners full practice authority are ongoing.

• New Jersey: Perhaps the most comprehensive requirements in the nation—New Jersey mandates an extensive initial evaluation including physical exam, laboratory tests, psychological screening, and a personalized diet/exercise plan. Patients must also provide informed consent covering all risks associated with weight-loss therapy.

• North Dakota: State medical board guidance expects a hands-on initial evaluation for weight-loss treatment, though telehealth is otherwise fully embraced.

• South Carolina: Requires an initial in-person visit and periodic evaluations. Nurse practitioners and physician assistants can prescribe with physician oversight.

• Texas: While Texas has broad telehealth laws, the standard of care typically requires an initial in-person exam for weight management. The state maintains strict oversight of prescriptive authority, requiring physician delegation agreements for nurse practitioners and physician assistants.

• Utah: State guidelines recommend an in-person baseline evaluation, though nurse practitioners have gained full practice authority as of 2023.

• Virginia: Requires an initial physical examination, laboratory work, and a personalized diet and exercise plan. Follow-up within 30 days of starting therapy is also mandated. After two years of collaborative practice, nurse practitioners can practice independently.

States with Ongoing Monitoring Requirements

Beyond initial visits, some states mandate regular follow-up:

Florida stands out with specific rules requiring:

• BMI of 30 or higher (or 27+ with comorbidities)
• Follow-up visits at least every three months during active treatment
• Documentation of lifestyle modification attempts

Who Can Prescribe Weight Loss Medications via Telehealth?

Provider qualifications vary significantly by state, which affects your telehealth options:

Physicians (MDs and DOs)

All states allow licensed physicians to prescribe GLP-1 medications via telehealth, provided they’re licensed in the state where the patient is located. This is the most straightforward pathway.

Nurse Practitioners (NPs)

The landscape for NP prescribing authority is evolving rapidly. As of December 2025:

Full Practice Authority States (NPs can prescribe independently):

• California, Connecticut, Delaware, Illinois, New York, North Dakota, Utah, Virginia (after experience requirements), Washington, and 25+ other states

Collaborative Practice States (NPs require physician oversight):

• Arkansas, Florida, Georgia, Mississippi, Pennsylvania, South Carolina, Texas

In collaborative practice states, nurse practitioners must have a formal agreement with a supervising physician. This doesn’t necessarily mean the physician must be present for each consultation, but there must be an established relationship for oversight purposes.

Physician Assistants (PAs)

Physician assistants can prescribe GLP-1 medications in all states, but they universally require some level of physician supervision or collaboration. The specific requirements vary by state.

Important note for patients: When using telehealth services like Klarity Health, you may be matched with an NP or PA depending on your state’s regulations and provider availability. This is completely normal and legal—these providers are fully qualified to manage weight loss treatment within their scope of practice.

What to Expect During Your Telehealth Visit

Legitimate telehealth weight loss programs follow a structured process to ensure patient safety and appropriate prescribing:

1. Comprehensive Medical History

Before your consultation, you’ll complete a detailed questionnaire covering:

• Current height, weight, and BMI calculation
• Medical history, including heart disease, thyroid conditions, pancreatitis, or gallbladder issues
• Current medications and supplements
• Pregnancy status and family planning
• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Previous weight loss attempts and outcomes
• Mental health history

2. Live Video Consultation

A licensed provider will conduct a real-time video visit to:

• Review your medical history and weight loss goals
• Discuss realistic expectations (typically 10-15% body weight loss over several months)
• Explain how GLP-1 medications work and potential side effects
• Assess contraindications that would make these medications unsafe for you
• Create a comprehensive treatment plan including diet and exercise recommendations
• Answer your questions about treatment

Red flag: Any service that prescribes these medications without a live consultation with a licensed clinician should be avoided. A simple questionnaire is never sufficient for appropriate prescribing.

3. Obtaining Informed Consent

Your provider will discuss:

• Common side effects like nausea, vomiting, diarrhea, and constipation
• Serious but rare risks including pancreatitis, gallbladder disease, and thyroid tumors
• The importance of lifestyle modifications alongside medication
• What to do if you experience concerning symptoms
• The need for ongoing monitoring and follow-up

Many states legally require documented informed consent specifically for weight-loss medications.

4. Laboratory Testing

While not required in all states, responsible providers typically request:

• Basic metabolic panel (kidney and liver function)
• Hemoglobin A1C (diabetes screening)
• Thyroid function tests
• Lipid panel

Some providers can arrange for at-home lab testing or provide orders for local lab facilities.

5. Prescription and Pharmacy Coordination

If you’re deemed an appropriate candidate, your provider will:

• Send an electronic prescription to your chosen pharmacy
• Provide injection training resources (these medications are self-administered subcutaneously)
• Schedule follow-up appointments (typically within 4-6 weeks initially)
• Coordinate with your insurance if applicable

Understanding the Medications: Wegovy, Ozempic, and Mounjaro

Let’s clarify what each medication is approved for and how they’re used in telehealth:

Wegovy (Semaglutide 2.4 mg)

FDA Approval: Chronic weight management in adults with BMI ≥30, or ≥27 with weight-related comorbidities

Telehealth Status: ✅ Fully prescribable via telehealth in compliant states

Typical Use: Once-weekly subcutaneous injection, starting at 0.25 mg and titrating up to 2.4 mg over 16-20 weeks

Key Points:

• This is the FDA-approved dose specifically for weight loss
• Should always be combined with lifestyle interventions
• Not a controlled substance—no DEA restrictions
• Electronic prescribing required in most states

Ozempic (Semaglutide 0.5-1 mg)

FDA Approval: Type 2 diabetes management

Off-Label Use: Weight loss (commonly prescribed off-label when Wegovy is unavailable or for cost reasons)

Telehealth Status: ✅ Prescribable via telehealth, but requires documentation of off-label use rationale

Key Points:

• Same active ingredient as Wegovy, lower maximum dose
• Insurance may cover for diabetes but not weight loss
• Providers must obtain informed consent for off-label use
• Cannot be combined with Wegovy (same medication)

Mounjaro (Tirzepatide) / Zepbound

FDA Approval: Mounjaro for Type 2 diabetes; Zepbound (same drug, higher dose) for obesity

Telehealth Status: ✅ Prescribable via telehealth in most states

Key Points:

• Dual GIP/GLP-1 receptor agonist (different mechanism than semaglutide)
• Often produces greater weight loss than semaglutide
• Supplied in single-dose pens or titration packs
• Requires patient training on self-injection technique

The Cost Factor: Insurance vs. Cash Pay

Weight loss medication costs vary dramatically based on insurance coverage:

Insurance Coverage

Many insurance plans now cover GLP-1 medications for weight loss, though coverage varies:

• Medicare does not cover weight loss medications (only diabetes-approved uses)
• Private insurance may require prior authorization and documentation of BMI criteria
• Copays typically range from $25-$200 per month with insurance

Klarity Health accepts both insurance and cash pay, making treatment accessible regardless of your coverage situation. Our team can help verify your benefits and determine the most cost-effective approach.

Cash Pay Options

Without insurance, brand-name GLP-1 medications can cost $900-$1,500 per month. However:

• Some telehealth providers negotiate discounted cash prices
• Manufacturer savings programs may reduce costs for eligible patients
• Generic versions are not yet available but may arrive in coming years

Important FDA Action: In May 2025, the FDA banned most compounded versions of semaglutide after declaring the shortage resolved. While compounded versions were cheaper, they weren’t FDA-approved and raised safety concerns. Stick with FDA-approved medications from licensed pharmacies.

Red Flags: How to Spot Illegitimate Telehealth Services

The popularity of GLP-1 medications has unfortunately attracted some unscrupulous operators. Watch out for:

Warning Signs of Problematic Services

❌ Guaranteed prescriptions: Any service promising you’ll definitely get a prescription without evaluation

❌ No live provider consultation: Legitimate care requires speaking with a licensed clinician

❌ Compounded or overseas versions: Since the FDA ban, these are generally illegal and potentially dangerous

❌ No follow-up care: Weight management requires ongoing monitoring, not one-time prescribing

❌ Unclear provider credentials: You should know exactly who is prescribing and in which state they’re licensed

❌ Pressure tactics: Reputable providers discuss alternatives and will decline to prescribe if you’re not an appropriate candidate

❌ No discussion of risks: If a service minimizes side effects or doesn’t obtain informed consent, that’s a major red flag

What Legitimate Services Look Like

✅ Thorough medical screening before any prescriptions

✅ Clear information about provider qualifications and licensing

✅ Transparent pricing for both consultations and medications

✅ Regular follow-up appointments to monitor progress and side effects

✅ Comprehensive approach including lifestyle counseling

✅ Coordination with your existing healthcare providers when appropriate

✅ Clear protocols for handling emergencies or adverse reactions

Klarity Health maintains the highest standards for telehealth weight management, with licensed providers in multiple states, transparent pricing, and comprehensive follow-up care. We never guarantee prescriptions—we guarantee thorough, evidence-based evaluation to determine if GLP-1 therapy is right for you.

Clinical Eligibility: Who Qualifies for GLP-1 Weight Loss Treatment?

Not everyone seeking weight loss is an appropriate candidate for these medications. Standard criteria include:

General Requirements

BMI Criteria:

• BMI ≥30 (obesity), OR
• BMI ≥27 with at least one weight-related comorbidity such as:
• Type 2 diabetes or prediabetes
• High blood pressure
• High cholesterol
• Sleep apnea
• Cardiovascular disease

Lifestyle Modification:

• Previous attempts at diet and exercise (unless medically contraindicated)
• Willingness to commit to ongoing lifestyle changes
• Understanding that medication is an adjunct to, not replacement for, healthy habits

Absolute Contraindications

You should not take GLP-1 medications if you have:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning to become pregnant (discontinue 2 months before conception)
• History of severe allergic reaction to semaglutide or tirzepatide
• Active or recent pancreatitis
• Severe gastroparesis or gastrointestinal disorders

Relative Contraindications (Require Careful Consideration)

• History of gallbladder disease
• Kidney disease (dose adjustments may be needed)
• Diabetic retinopathy (requires monitoring)
• Depression or suicidal ideation (emerging safety data requires caution)
• Taking other weight loss medications

The Role of Follow-Up Care in Telehealth Weight Management

One of the most important aspects of responsible telehealth weight loss treatment is ongoing monitoring:

Initial Phase (First 3 Months)

• Week 4-6: First follow-up to assess tolerance, side effects, and early response
• Monthly check-ins: Weight tracking, side effect management, dose titration
• Labs at 3 months: Metabolic panel, A1C if diabetic, lipid panel

Maintenance Phase (Months 4-12)

• Every 2-3 months: Progress evaluation, medication adjustment as needed
• Every 6 months: Comprehensive labs, blood pressure check, review of cardiovascular risk factors
• Ongoing: Access to provider messaging for questions or concerns

What Providers Monitor

• Efficacy: Weight loss trajectory (expect 1-2 pounds per week initially)
• Side effects: Gastrointestinal symptoms, changes in appetite, any concerning symptoms
• Safety labs: Kidney function, liver enzymes, blood sugar
• Lifestyle integration: Diet quality, physical activity, behavioral changes
• Psychological wellbeing: Mood changes, relationship with food, body image

Some states mandate specific follow-up intervals—for example, Florida requires visits at least every 3 months, and Virginia requires follow-up within 30 days of starting therapy.

The Future of Telehealth Weight Loss Care

As we move into 2026 and beyond, several trends are shaping access to GLP-1 medications:

Regulatory Developments

DEA Telehealth Rules: While the current extension for controlled substances expires December 31, 2025, additional extensions are expected. Congress is also considering the TREATS Act, which would make some telehealth flexibilities permanent. These developments, while focused on controlled medications, signal broad federal support for telemedicine.

State Modernization: More states are expected to update their telehealth laws and expand nurse practitioner practice authority. Bills pending in Mississippi, Pennsylvania, and other states could make telehealth weight loss care more accessible in 2026.

Interstate Compacts: Increasing participation in interstate licensure compacts for both physicians and nurse practitioners will make it easier for telehealth providers to serve patients across state lines.

Clinical Advances

New GLP-1 and dual-agonist medications are in development, potentially offering:

• Once-monthly or less frequent dosing
• Oral formulations (semaglutide oral is already available for diabetes)
• Triple-agonist medications targeting additional metabolic pathways
• Medications with fewer gastrointestinal side effects

Access and Affordability

• Generic versions of semaglutide may arrive in the coming years, significantly reducing costs
• More insurance plans are adding weight loss medication coverage as evidence grows
• Telehealth platforms are negotiating better pricing arrangements with manufacturers and pharmacies

How to Get Started with Telehealth Weight Loss Treatment

If you’re ready to explore GLP-1 medications for weight management, here’s your roadmap:

Step 1: Gather Your Information

Before your consultation, compile:

• Current and past medical records
• List of current medications and supplements
• Recent lab results (if available)
• Your weight history and previous weight loss attempts
• Your specific health and weight goals

Step 2: Choose a Reputable Telehealth Provider

Look for services that offer:

• Licensed providers in your state
• Transparent pricing (consultation and medication costs)
• Comprehensive initial evaluation
• Regular follow-up care
• Both insurance and cash pay options
• Clear communication channels for questions

Klarity Health checks all these boxes, with providers available in multiple states, same-week appointments, and pricing transparency from your first inquiry.

Step 3: Complete Your Initial Consultation

During your visit:

• Be honest about your medical history and weight loss goals
• Ask questions about treatment options, expected results, and potential side effects
• Discuss any concerns about cost or insurance coverage
• Understand the commitment required for successful treatment

Step 4: Begin Treatment with Realistic Expectations

If prescribed:

• Follow all injection instructions carefully
• Report any side effects to your provider
• Commit to lifestyle changes alongside medication
• Attend all scheduled follow-up appointments
• Be patient—meaningful weight loss takes time (typically 10-15% over 6-12 months)

Step 5: Maintain Long-Term Success

• Continue regular check-ins even after reaching your goal weight
• Work with your provider to develop a maintenance plan
• Address any weight regain promptly
• Stay engaged with healthy lifestyle habits

State-Specific Considerations: A Quick Reference

If You Live in California, New York, or Washington

These states offer the most straightforward telehealth access with minimal restrictions. Nurse practitioners can practice independently, and no in-person visits are required. You can complete your entire weight loss journey via virtual care.

If You Live in Texas, Florida, or Georgia

Be prepared for potentially requiring an initial in-person visit or working with a provider who has physician oversight. Texas in particular maintains strict collaborative practice requirements. However, telehealth follow-ups are fully permitted once the initial evaluation is complete.

If You Live in New Jersey or Virginia

Expect comprehensive initial requirements including physical exam, laboratory work, and documented lifestyle counseling. These states prioritize thorough evaluation, which may mean more upfront work but ensures appropriate patient selection and safety.

If You’re Traveling or Moving Between States

Remember that your provider must be licensed in the state where you are physically located during the consultation. If you’re temporarily in another state, you may need to wait until returning home for your appointment, or work with a provider licensed in multiple states.

Take the Next Step Toward Your Weight Loss Goals

Telehealth has transformed access to evidence-based weight management, making GLP-1 medications available to millions of Americans who might otherwise struggle with traditional in-person care. Whether you’re dealing with a busy schedule, limited access to specialized obesity medicine providers in your area, or simply prefer the convenience of virtual care, telehealth offers a legitimate and effective pathway to treatment.

The key is choosing a provider who prioritizes your safety, offers comprehensive evaluation and ongoing support, and operates transparently within your state’s regulations. With the right telehealth partner, you can access the same quality of care you’d receive in a traditional clinic—often with greater convenience and affordability.

Ready to explore whether GLP-1 medications are right for you? Klarity Health offers consultations with licensed providers in multiple states, with appointments available as soon as this week. We accept most insurance plans and offer transparent cash-pay pricing for those without coverage. Our providers will conduct a thorough evaluation, answer all your questions, and help you make an informed decision about weight loss treatment.

Your journey to sustainable weight loss and better health could start with a single virtual visit. Don’t let geographic barriers or busy schedules stand between you and the care you deserve.

Frequently Asked Questions

Q: Is it legal to get Wegovy or Ozempic prescribed online?

A: Yes, it’s legal in all 50 states to receive GLP-1 prescriptions via telehealth, though some states require an initial in-person visit. These medications are not controlled substances, so federal telehealth restrictions don’t apply.

Q: Will my insurance cover telehealth weight loss visits?

A: Most insurance plans now cover telehealth visits at the same rate as in-person appointments. However, coverage for the medications themselves varies. Klarity Health can help verify your benefits before your appointment.

Q: How do I know if a telehealth weight loss service is legitimate?

A: Look for services that require live video consultations with licensed providers, clearly state provider credentials and licensing, offer ongoing follow-up care, and never guarantee prescriptions before evaluating you.

Q: Can nurse practitioners prescribe weight loss medications?

A: Yes, nurse practitioners can prescribe GLP-1 medications in all states, though some require physician collaboration. The prescriber’s training and experience matter more than their professional designation.

Q: What if I experience side effects?

A: Reputable telehealth services provide ongoing access to your provider for questions and concerns. Most side effects can be managed with dose adjustments or supportive care. Your provider should be available via secure messaging or phone for urgent concerns.

Research and Sources

This article is based on current federal regulations, state-specific telehealth laws, and FDA-approved prescribing information verified as of December 17, 2025.

Top 5 Primary Sources:

1. U.S. Drug Enforcement Administration (DEA) – ‘DEA and HHS Extend Telemedicine Flexibilities Through 2025’ (November 15, 2024). Official announcement confirming federal telehealth prescribing rules for controlled substances through December 31, 2025. www.dea.gov

2. McDermott Will & Emery Law Firm – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ (November 18, 2024). Expert legal analysis of DEA regulations and the distinction between controlled and non-controlled medications in telehealth prescribing. www.mwe.com

3. Goodwin Procter LLP – ‘The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs’ (March 27, 2024). Comprehensive review of state-specific regulations for weight loss medication prescribing, including detailed requirements for Florida, New Jersey, and Virginia. www.goodwinlaw.com

4. Reuters – ‘Hims to cut 4% of workforce amid ban on weight-loss drug copies’ (May 30, 2025). Report on FDA enforcement action banning compounded semaglutide and impact on telehealth industry. www.reuters.com

5. Nextech Systems – ‘Know Your State’s Laws Around Semaglutide’ (April 11, 2025). State-by-state compilation of telehealth prescribing requirements, in-person visit mandates, and provider authority regulations for GLP-1 medications. www.nextech.com

Additional Referenced Sources:

• U.S. Senator Lisa Murkowski – ‘Murkowski, Whitehouse, Tillis, and Warner Reintroduce Bipartisan Legislation to Expand Telehealth Access’ (October 28, 2025) – Information on pending TREATS Act legislation
• Texas Medical Board – ‘Prescribing and Supervision FAQs’ (2025) – State-specific guidance on NP/PA prescribing authority
• National Law Review – ‘Arkansas: At it Again – Telemedicine Regulation in Arkansas Undergoes Additional Change’ (2024) – Analysis of state telehealth law variations
• Nurse Practitioner Online – ‘Nurse Practitioner Practice Authority: 2025 Updates’ (December 4, 2025) – Current status of NP independence by state

All sources were verified as current as of December 17, 2025. Federal and state regulations are subject to change; readers should confirm current requirements with licensed providers in their state.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid